← All trials
NCT06528314
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 4, 2024
- Primary completion
- Sep 30, 2029
- Completion date
- Oct 31, 2029
- First posted
- Jul 30, 2024
- Last posted
- Oct 16, 2024
- Enrollment
- 1150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Akero Therapeutics, IncLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.